NCT06100510View on ClinicalTrials.gov

PFA 100 Evaluation and Reference Interval HOACNY

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

October 10, 2024

Study Completion Date

October 10, 2024

Conditions
Effect of Drug
Interventions
DRUG

Aspirin 325mg

Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.

Trial Locations (1)

13057

Hematology Oncology Associates of Central New York, East Syracuse

All Listed Sponsors
lead

Hematology Oncology Associates of Central New York

OTHER